Arbortristoside A
Arbortristoside A is an orally active inhibitor of prostaglandin (prostaglandin), histamine (histamine) and serotonin (serotonin). Arbortristoside A mediates anti-inflammatory, analgesic, anti-allergic, immunomodulatory, antiviral and anti-ulcerogenic effects, and also exhibits in vitro anticancer activity. Arbortristoside A can be used in research related to human hepatocellular carcinoma, breast cancer, fibrosarcoma, leishmaniasis, allergic diseases, viral infections and gastric ulcers.
For research use only. We do not sell to patients.
- CAS No.: 97145-52-3
- Formula: C27H34O13
- Molecular Weight:566.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Arbortristoside-A (50-75 mg/kg; i.p.; single administration) dose-dependently inhibits acetic acid (HY-Y0319)-induced writhing response in Swiss albino mice[1].
Arbortristoside-A (50-75 mg/kg; i.p.; single administration) dose-dependently prolongs the pain response time of Swiss albino mice tested by the Eddy hot-plate method[1].
Arbortristoside A (10-40 mg/kg; p.o.; single administration) dose-dependently protects rats against cold restraint stress-induced gastric ulcers[4].
Arbortristoside A (20 mg/kg; p.o.; single dose) exerts a significant protective effect against ethanol-induced gastric ulcers in rats[4].
Arbortristoside A (20 mg/kg; p.o.; single administration) exerts a 48.45% protective effect against Aspirin (HY-14654)-induced gastric ulcers in rats[4].
Arbortristoside A (20 mg/kg; p.o.; single administration) exerts a 50.0% protective effect against pylorus ligation-induced gastric ulcers in rats, while reducing gastric acid secretion and increasing mucin production[4].
Arbortristoside A (20 mg/kg; p.o.; once daily; for 10 consecutive days) increases the healing rate of acetic acid-induced chronic gastric ulcers in rats to 55.94%[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar albino (weighing 150-180 g)[1]
-
Dosage:50, 75 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced paw edema.
-
Animal Model:Swiss albino (weighing 18-22 g)[1]
-
Dosage:50, 75 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced Acetic acid-induced writhing counts.
-
Animal Model:Swiss albino (weighing 18-22 g; fasted for 12 hours with access to water)[1]
-
Dosage:50, 75 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased pain reaction time.
-
Animal Model:Sprague-Dawley (adult female, 180-220 g, chronic acetic acid-induced)[4]
-
Dosage:20 mg/kg
-
Administration:p.o.; daily; 10 days
-
Result:Provided 55.94% ulcer healing compared to controls.
Increased gastric mucosal PGE2 levels to 3857 pg/mg protein from control level of 2551 pg/mg protein.
Restored mucosal epithelium, reduced inflammatory exudates, and improved glandular organization based on histopathology.
Suppressed ulcer-induced increase in TNF-α and IL-1β mRNA expression.
Left COX-1 expression unchanged relative to sham and control groups.
Chemical Information
-
CAS No. 97145-52-3
-
Molecular Weight 566.55
-
Formula C27H34O13
-
SMILES
COC(C=C1)=CC=C1/C=C/C(O[C@H]2[C@@]3([H])[C@]([C@H]([C@H]2O)C)([H])[C@@H](OC=C3C(OC)=O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)